YONGIN, South Korea, Sept. 23, 2025 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed for its cervical cancer diagnostic cartridge miLab™ Cartridge CER and clearing agent SafeFix™ CER, both core components of the company's cervical cancer diagnostic solution miLab™ CER. Noul's miLab CER automates cervical cytology with an integrated AI-powered system that performs sample preparation, imaging, and analysis. The product was named one of the three recommended technologies for cervical cancer triage — alongside Roche and Hologic — in the 2024 WHO–Unitaid report. About Noul Co., Ltd."Enabling blood and cancer diagnostics anywhere in the world with AI." With strong clinical validation and proven performance, Noul is rapidly expanding its market presence, especially in malaria, blood analysis, and cervical cancer diagnostics.